Clinical trial
A Phase I Study of Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.
NCT00332215 · University of Minnesota, Other · Terminated
Key facts
| NCT number | NCT00332215 |
|---|---|
| Title | A Phase I Study of Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis. |
| Official title | Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis. A Phase I, Double Blind, Placebo Controlled, Safety Study. |
| Lead sponsor | University of Minnesota, Other |
| Collaborators | Cellular Sciences, inc. Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cystic Fibrosis |
| Intervention type | Drug |
| Interventions | Inhaled Sodium Pyruvate |
| Enrollment | 70 |
| Start date | Feb 1, 2006 |
| First posted | Jun 1, 2006 |
| Last update posted | Dec 1, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: